סימבקסון 40

Country: Israel

Bahasa: Ibrani

Sumber: Ministry of Health

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
06-07-2021

Bahan aktif:

SIMVASTATIN

Boleh didapati daripada:

DEXCEL PHARMA TECHNOLOGIES LTD

Kod ATC:

C10AA01

Borang farmaseutikal:

קפליות

Komposisi:

SIMVASTATIN 40 MG

Laluan pentadbiran:

פומי

Jenis preskripsi:

מרשם נדרש

Dikeluarkan oleh:

DEXCEL LTD, ISRAEL

Kumpulan terapeutik:

SIMVASTATIN

Kawasan terapeutik:

SIMVASTATIN

Tanda-tanda terapeutik:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

Ringkasan produk:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

Tarikh kebenaran:

2020-04-30

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Inggeris 20-01-2021
Laporan Penilaian Awam Laporan Penilaian Awam Inggeris 18-08-2016
Risalah maklumat Risalah maklumat Arab 20-01-2021

Cari amaran yang berkaitan dengan produk ini